JNJJohnson & JohnsonMega cap · $620.51B · FY ending 2025-12-28
$257.77+0.31% · 2026-07-13 · EOD
64/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality78
narrow moat · ROIC 16%Value44
P/E 23.4 · 92% of 12-mo rangeMomentum73
golden · price above 200-daySmart Money60
buying · 0 funds · 0P/4S insidersBullish stackGolden crossAbove 200-day
vs S&P 500+16.6%
6-mo excess Trailing performance1M +8.1%
3M +8.1%
6M +25.3%
YTD +24.3%
1Y +63.5%
P/E vs its last 12 months (our price history): 14.1 low → 24.2 high
Current price sits at the 92th percentile of that window — near the top (richer). We only compare against the price history we own (no paid multi-year multiples — nothing invented).
Narrow moat — ROIC 16%
Piotroski F3/9
fundamental strength ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of 18%. Annual figures from SEC XBRL.
Dividend & capital return
Shareholder yield1.0%
dividends + buybacks Annual figures from SEC cash-flow statements. Shareholder yield = total cash returned ÷ market cap.
Net buying0P / 4S insiders · 0 funds hold · 1 Congress buys
Recent insidersWengel Kathryn E · EVP, Chief TO and Risk OfficerSELL$2.4M
Decker Robert J · VP Corporate ControllerSELL$1.0M
Schmid Timothy · EVP, WW Chair, MedTechSELL$324,763
Swanson James D. · EVP, CIOSELL$15.1M
CongressLloyd DoggettBUY2026-06-09
Rohit Khanna
Chealth · 66/100
Self-fundingSelf-funding — profitable · generates cash
No red flags from its filings.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.